Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease

被引:11
|
作者
Ueceyler, Nurcan [1 ,3 ]
Schroeter, Nils [1 ,3 ]
Kafke, Waldemar [1 ,3 ]
Kramer, Daniela [1 ,3 ]
Wanner, Christoph [2 ,3 ]
Weidemann, Frank [2 ,3 ,4 ]
Sommer, Claudia [1 ,3 ]
机构
[1] Univ Wurzburg, Dept Neurol, Wurzburg, Germany
[2] Univ Wurzburg, Dept Internal Med, Wurzburg, Germany
[3] Univ Wurzburg, Wurzburg Fabry Ctr Interdisciplinary Therapy FAZI, Wurzburg, Germany
[4] Katharinen Hosp Unna, Innere Klin 2, Obere Husemannstr 2, D-59423 Unna, Germany
来源
PLOS ONE | 2016年 / 11卷 / 11期
关键词
ENZYME REPLACEMENT THERAPY; PAIN SYMPTOM INVENTORY; SMALL FIBER NEUROPATHY; AGALSIDASE-BETA; DIAGNOSIS; NEPHROPATHY; BIOPSIES; EFFICACY; SAFETY; TRIAL;
D O I
10.1371/journal.pone.0166484
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity. Methods At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data. Results We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy. Conclusions Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Autonomic skin responses in females with Fabry disease
    Moller, Anette T.
    Bach, Flemming W.
    Feldt-Rasmussen, Ulla
    Rasmussen, Ase K.
    Hasholt, Lis
    Sommer, Claudia
    Kolvraa, Steen
    Jensen, Troels Staehelin
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2009, 14 (03) : 159 - 164
  • [22] Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art
    Ponsiglione, Andrea
    De Giorgi, Marco
    Ascione, Raffaele
    Nappi, Carmela
    Sanduzzi, Luca
    Pisani, Antonio
    Dell'Aversana, Serena
    Cuocolo, Alberto
    Imbriaco, Massimo
    DIAGNOSTICS, 2023, 13 (15)
  • [23] Novel Quantitative Method to Evaluate Globotriaosylceramide Inclusions in Renal Peritubular Capillaries by Virtual Microscopy in Patients With Fabry Disease
    Barisoni, Laura
    Jennette, J. Charles
    Colvin, Robert
    Sitaraman, Sheela
    Bragat, Alexander
    Castelli, Jeff
    Walker, Dan
    Boudes, Pol
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (07) : 816 - 824
  • [24] Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications
    Weidemann, F.
    Niemann, M.
    Stoerk, S.
    Breunig, F.
    Beer, M.
    Sommer, C.
    Herrmann, S.
    Ertl, G.
    Wanner, C.
    JOURNAL OF INTERNAL MEDICINE, 2013, 274 (04) : 331 - 341
  • [25] Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa
    Schiffmann, Raphael
    Ries, Markus
    Blankenship, Derek
    Nicholls, Kathy
    Mehta, Atul
    Clarke, Joe T. R.
    Steiner, Robert D.
    Beck, Michael
    Barshop, Bruce A.
    Rhead, William
    West, Michael
    Martin, Rick
    Amato, David
    Nair, Nitin
    Huertas, Pedro
    GENETICS IN MEDICINE, 2013, 15 (12) : 983 - 989
  • [26] Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
    Shiga, Tomoko
    Tsukimura, Takahiro
    Namai, Yurie
    Togawa, Tadayasu
    Sakuraba, Hitoshi
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2021, 29
  • [27] Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease
    Arends, Maarten
    Wijburg, Frits A.
    Wanner, Christoph
    Vaz, Frederic M.
    van Kuilenburg, Andre B. P.
    Hughes, Derralynn A.
    Biegstraaten, Marieke
    Mehta, Atul
    Hollak, Carla E. M.
    Langeveld, Mirjam
    MOLECULAR GENETICS AND METABOLISM, 2017, 121 (02) : 157 - 161
  • [28] How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
    Auray-Blais, Christiane
    Ntwari, Aime
    Clarke, Joe T. R.
    Warnock, David G.
    Oliveira, Joao Paulo
    Young, Sarah P.
    Millington, David S.
    Bichet, Daniel G.
    Sirrs, Sandra
    West, Michael L.
    Casey, Robin
    Hwu, Wuh-Liang
    Keutzer, Joan M.
    Zhang, X. Kate
    Gagnon, Rene
    CLINICA CHIMICA ACTA, 2010, 411 (23-24) : 1906 - 1914
  • [29] Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease
    Kanai, Takahiro
    Ito, Takane
    Odaka, Jun
    Saito, Takashi
    Aoyagi, Jun
    Betsui, Hiroyuki
    Yamagata, Takanori
    EUROPEAN JOURNAL OF PEDIATRICS, 2016, 175 (03) : 427 - 431
  • [30] Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy
    Ohashi, Toya
    Sakuma, Mio
    Kitagawa, Teruo
    Suzuki, Ken
    Ishige, Nobuyuki
    Eto, Yoshikatsu
    MOLECULAR GENETICS AND METABOLISM, 2007, 92 (03) : 271 - 273